Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to...

Descripción completa

Detalles Bibliográficos
Autores principales: Golestani, Mina, Eshghi, Peyman, Rasekh, Hamid Reza, Cheraghali, Abdoll Majid, Salamzadeh, Jamshid, Naderi, Majid, Managhchi, Mohammad Reza, Hoorfar, Hamid, Toogeh, Gholam Reza, Imani, Ali, Khodayari, Mohammad Taghi, Habibpanah, Behnaz, Hantooshzadeh, Razieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018298/
https://www.ncbi.nlm.nih.gov/pubmed/27642341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018298/
https://www.ncbi.nlm.nih.gov/pubmed/27642341

Ejemplares similares